Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects

Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W81XWH19C0130
Agency Tracking Number: H19A-001-0007
Amount: $162,499.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: DHA19A-001
Solicitation Number: 2019.1
Timeline
Solicitation Year: 2019
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-07-24
Award End Date (Contract End Date): 2020-02-24
Small Business Information
2531 West 237th Street, Torrance, CA, 90505
DUNS: 114060861
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Dr. Aynun Begum
 (310) 530-2011
 aynun.begum-1@innosensellc.com
Business Contact
 Dr. Kisholoy Goswami
Phone: (310) 530-2011
Email: kisholoy.goswami@innosensellc.com
Research Institution
 Beckman Research Inst
 Jaclyn Lucas
 1500 East Duarte Road
Duarte, CA, 91010
 (626) 256-4673
 Domestic nonprofit research organization
Abstract
Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trauma deaths. There are many types of coagulation defects, which need distinct interventions. Therefore, DHA wants prompt monitoring of the underlying cause of each individual blood clotting defect.To determine underlying cause of blood coagulopathy, InnoSense LLC (ISL) and City of Hope propose to develop a single walled carbon nanotube-based multiplex sensor array, BloodCLO. It will detect blood coagulopathy biomarkers in 10 minutes or less with at least 90% sensitivity and specificity. In Phase I, ISL will fabricate the biosensor and detect a panel of blood coagulopathy biomarkers, such as platelet, fibrinogen and thrombin in blood samples as an indicator of blood clot time and strength using a laboratory prototype. In Phase II, ISL will optimize the fabrication steps for scale-up, evaluate and validate the prototype design. In Phase III, ISL will seek FDA approval toward market entry. BloodCLO will be simple and rapid, easy to use, accurate and suitable for regular screening and monitoring in POC setting with small blood sample (~25 microliters).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government